At a glance
In Canada, we currently employ approximately 1,628 full time employees across the country, providing a salary injection of $94 million into the Canadian economy. We have two divisional headquarters in Mississauga, Ontario and Montréal, Quebec, and an administrative office in Quebec City.

Locations
Manufacturing
The Ste-Foy vaccine manufacturing site currently produces an important share of Canada’s seasonal influenza vaccine and responsible for the domestic supply of the country’s pandemic influenza vaccine requirements.
Research & development

We have invested more than $2 billion since 2001 in Canadian pharmaceutical and vaccines Research & Development (R&D), with over 121 million in 2023 alone. In 2023, we invested over $18.4 million into 53 active clinical trials across Canada involving 3,334 active subjects.
We are committed to working in partnership with charities and community based organizations who reflect our key values, supporting programs with a local, national or international reach.
Environmental sustainability

In October 2018, we launched a Centralized Waste program involving the removal of individual waste containers from offices to promote environmental consciousness and reduce our contribution to landfills.
In November 2020, as a global biopharmaceutical company we announced ambitious new environmental sustainability goals in both climate and nature, aiming to have a net zero impact on climate and a net positive impact on nature by 2030, across our entire value chain – from lab to patient. We’ve set clear and measurable targets to help achieve these goals.

Global GSK at a glance
Learn more about some of our key achievements in pursuing our purpose to get ahead of disease.